Berkeley Lights, Inc.
5858 Horton Street
About Berkeley Lights, Inc.
Founded in 2011 and headquartered in Emeryville, CA, Berkeley Lights, Inc. has developed technology, platforms and devices* that enable opto-nanofluidic biomedical engineering with the highest level of integration. Named a strategic partner with the Parker Institute for Cancer Immunology in April 2016, Berkeley Lights’ core belief is that biomedical challenges yield to world-class engineering. The company is applying its capabilities to address unmet research needs in BioPharma, Cellular Immuno-Oncology, and Autologous T-cell Therapies.
CEO: Igor Khandros
CBO: Drake Parker
CFO: Shaun Holt
CSO: Kevin Chapman
Please click here for Berkeley Lights job opportunities.
FOLLOW BERKELEY LIGHTS:
Tweets by Berkeley Lights
27 articles with Berkeley Lights, Inc.
Ginkgo Bioworks and Berkeley Lights Bring Unprecedented Speed and Scale to Synthetic Biology with $150MM Collaboration
Collaboration brings best-in-class technology to Ginkgo foundries, with a commitment to ongoing joint technology development
Berkeley Lights, Inc. announced the opening of a representative office in Pudong, Shanghai.
8/9/2019Biopharma companies strengthen their senior leadership teams and boards of directors.
Berkeley Lights to Launch New T Cell Functional Analytics Platform at the 34ᵗʰ Congress of the International Society for Advancement of Cytometry (CYTO)
Berkeley Lights, Inc. announced the launch of the LightningTM optofluidic platform, which directly visualizes phenotype and function of 1000s of T cells in days to help scientists address challenges in developing cancer immunotherapies.
Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services.
Berkeley Lights, Inc., a leader in digital cell biology, announced that it has been named one of Fast Company's 2019 Most Innovative Companies in Biotech.
Berkeley Lights calls itself a digital cell biology company. It develops and markets tech platforms for what it calls “the intersection of biology, technology and information.”
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
Shire's decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon.
Another Large Pharma Implements Berkeley Lights' Beacon OptoFluidic Platform for Accelerating Antibody Discovery
Berkeley Lights announced today that Novartis is implementing BLI's Beacon platform to help accelerate their antibody discovery workflow.
Through the collaboration, the companies will combine BLI's platform - which utilizes a light-based, nano-fluidic method to select, characterize, culture and export single cells - with Pfizer's expertise in gene editing, sequencing, and molecular biology, as well as B-cell screening, to help advance the research aims and influence the development of the Beacon platform.
Berkeley Lights announced today a program with Daiichi Sankyo focused on using the Beacon platform to accelerate its cell line development workflow.
Berkeley Lights Automates Biological Processing To Reduce Drug Development Timelines And Bring Therapies To Market Faster
Berkeley Lights Announces Strategic Project With Bayer Focused On Cell Line Development And Antibody Discovery